Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. “We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a “breakthrough” drug by the FDA last April based on initial data from the trial. The FDA grants “breakthrough” status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
[A]: Pfizer Inc’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.


[Q]: Paragraph: Older adults who underwent a brief course of brain exercises saw improvements in reasoning skills and processing speed that could be detected as long as 10 years after the course ended, according to results from the largest study ever on cognitive training. The findings, published on Monday in the Journal of the American Geriatrics Society, offer welcome news in the search for ways to keep the mind sharp as 76 million baby boomers in the United States advance into old age. The federally sponsored trial of almost 3,000 older adults, called the Advanced Cognitive Training for Independent and Vital Elderly study, or ACTIVE, looked at how three brain training programs - focusing on processing speed, memory and reasoning ability - affected cognitively normal adults as they aged. People in the study had an average age of 74 when they started the training, which involved 10 to 12 sessions lasting 60 to 75 minutes each. After five years, researchers found, those with the training performed better than their untrained counterparts in all three measures. Although gains in memory seen at the study’s five-year mark appeared to drop off over the next five years, gains in reasoning ability and processing speed persisted 10 years after the training. “What we found was pretty astounding. Ten years after the training, there was evidence the effects were durable for the reasoning and the speed training,” said George Rebok, an expert on aging and a professor at Johns Hopkins University in Baltimore, who led the study. Participants in all three training groups also reported that they had an easier time with daily activities such as managing their medications, cooking meals or handling their finances than did participants who did not get the training. But standard tests of these activities showed no differences between the groups. “The speed-of-processing results are very encouraging,” said study co-author Jonathan King, program director for cognitive aging in the Division of Behavioral and Social Research at the National Institute on Aging (NIA), part of the National Institutes of Health, which helped fund the research. King said the self-reported improvements in daily function were interesting, but added, “We do not yet know whether they would truly allow older people to live independently longer.”  However, researchers said even a small gain would be likely to ease the burden on caregivers and healthcare providers. “If we delay the onset of difficulties in daily activities even by a small amount, that can have major public health implications in terms of helping to curb healthcare costs, delaying entry into institutions and hospitals,” Rebok said. The training course was designed to bolster specific cognitive abilities that begin to slip as people age. It does not aim to prevent dementia caused by underlying disease such as Alzheimer’s. At the start of the study, all 2,832 participants were cognitively normal. The study included four groups: three training groups plus a control group of volunteers who came in for regular testing to see how they were faring with age. People were trained in small groups over a period of several weeks and then were tested immediately after the training and again one, two, three, five and 10 years later. About 60 percent of the volunteers who underwent training also got booster training sessions, which enhanced the initial benefits. At the end of the trial, all groups showed declines compared with their initial baseline tests in memory, reasoning and processing speed, but those who got training in reasoning and processing speed experienced less decline. Among those given training in reasoning strategies, 73.6 percent were still performing above their pre-trial baseline level, compared with 61.7 percent of those who received no training and were only benefiting from practice on the test. The effect was even greater in processing speed. Among the training group, 70.7 percent of participants were performing at or above their baseline level, compared with 48.8 percent of those in the control group. There was no difference in memory performance between the memory group and the control group after 10 years. Two of the three training programs - the memory and the reasoning strategies - were done with paper and pencil, while the processing speed training was done on a computer. The programs, developed by the researchers, were focused largely on teaching strategies to improve cognitive performance. For example, the memory training taught people how to remember word lists, sequences and main ideas, while the reasoning training focused on things like recognizing number patterns. In the processing speed training, people were asked to focus on the main object in a computer screen while also trying to quickly recognize and identify objects on the periphery of the screen. Such training can help older drivers with things like recognizing road signs while driving. A version of the speed training program developed for this trial is now commercially available through the brain fitness company Posit Science, but the researchers are working on making other types of training available as well. Rebok’s team just got a grant from the National Institute on Aging to make a computerized version of the memory test, with the hope that repeated training can improve the results. The study was not designed to explain why cognitive training can have such a lasting effect. Rebok said it may be that people take the strategies they learn and practice them over time. As they age, trained individuals can rely on these strategies to compensate for their declines. Whether this training actually strengthened the brain in the way that exercising builds muscle is not clear, but the government intends to study this, too. Last week, NIA put out a request for proposals that would study whether cognitive training causes physical changes in the brain. Claim: Brain training helped older adults stay sharp for years: study.
[A]: A brief course of brain exercises helped older adults hold on to improvements in reasoning skills and processing speed for 10 years after the course ended, according to results from the largest study ever done on cognitive training.


[Q]: Paragraph: The scientists, who treated the monkeys with a neuroprosthetic interface that acted as a wireless bridge between the brain and spine, say they have started small feasibility studies in humans to trial some components. “The link between the decoding of the brain and the stimulation of the spinal cord – to make this communication exist – is completely new,” said Jocelyne Bloch, a neurosurgeon at the Lausanne University Hospital who surgically placed the brain and spinal cord implants in the monkey experiments. “For the first time, I can imagine a completely paralyzed patient able to move their legs through this brain-spine interface.”  Gregoire Courtine, a neuroscientist at the Swiss Federal Institute of Technology (EPFL) which led the work, cautioned that there are major challenges ahead and “it may take several years before this intervention can become a therapy for humans.”  Publishing their results in the journal Nature on Wednesday, the team said the interface works by decoding brain activity linked to walking movements and relaying that to the spinal cord – below the injury – through electrodes that stimulate neural pathways and activate leg muscles. In bypassing the injury and restoring communication between the brain and the relevant part of the spinal cord, the scientists successful treated two rhesus monkeys each with one leg paralyzed by a partial spinal cord lesion. One of the monkeys regained some use of its paralyzed leg within the first week after injury, without training, both on a treadmill and on the ground, while the other took around two weeks to recover to the same point. “We developed an implantable, wireless system that operates in real-time and enabled a primate to behave freely, without the constraint of tethered electronics,” said Courtine. “We understood how to extract brain signals that encode flexion and extension movements of the leg with a mathematical algorithm. We then linked the decoded signals to the stimulation of specific hotspots in the spinal cord that induced the walking movement.”  The brain and spinal cord can adapt and recover from small injuries, but until now that ability has been far too limited to overcome severe damage. Other attempts to repair spinal cords have focused on stem cell therapy and on combinations of electrical and chemical stimulation of the cord. Independent experts not directly involved in this work said it was an important step towards a potential future where paralyzed people may be able to walk again. Simone Di Giovanni, a specialist in restorative neuroscience at Imperial College London, said EPFL’s results were “solid, very promising and exciting” but would need to be tested further in more animals and in larger numbers. “In principle this is reproducible in human patients,” he said. “The issue will be how much this approach will contribute to functional recovery that impacts on the quality of life. This is still very uncertain.” Claim: Paralyzed monkeys walk again with wireless 'brain-spine interface'.
[A]:
Swiss scientists have helped monkeys with spinal cord injuries regain control of non-functioning limbs in research which might one day lead to paralyzed people being able to walk again.